Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RSVI 303

Next Previous
X
Search
Drug Profile

RSVI 303

Alternative Names: RSVI-303

Latest Information Update: 21 Nov 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator RosVivo Therapeutics; University of Nevada Reno
  • Developer RosVivo Therapeutics
  • Class Antihyperglycaemics; Small interfering RNA
  • Mechanism of Action KLF11 protein expression inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Gastrointestinal motility disorders; Type 2 diabetes mellitus

Most Recent Events

  • 04 Oct 2022 RSVI 303 is available for licensing as of 04 Oct 2022. https://rosvivo.com/ (RosVivo Therapeutics website, October 2022).
  • 04 Oct 2022 Preclinical trials in Type 2 diabetes mellitus in USA (Parenteral) prior to October 2022
  • 04 Oct 2022 Preclinical trials in Gastrointestinal motility disorders in USA (Parenteral) prior to October 2022

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top